pSivida Corp., (NASDAQ: PSDV) (ASX: PVA) headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, the U.K. Spain, and Italy. ILUVIEN for DME has recently been approved in the US. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis with the same micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's two FDA-approved products, Retisert® and Vitrasert®, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

Type
Public
HQ
Watertown, US
Employees
26 (est)+74%
pSivida is headquartered in Watertown, US

pSivida Locations

Watertown, US
Worcestershire, GB

pSivida Metrics

pSivida Summary

Market capitalization

$62.2 M

Closing share price

$1.83
pSivida's current market capitalization is $62.2 M.

pSivida Financials

pSivida's revenue is $1.62 M in FY, 2016 which is 93.9% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$3.47 M$26.6 M$1.62 M

Operating income

$-13.5 M$6.42 M$-21.8 M

Operating expense total

$17 M$20.1 M$23.4 M

Net Income

$-13.4 M$6.35 M$-21.5 M

Operating cash flow

$8.44 M$3.79 M$-3.81 M

    pSivida Market Value History

    We estimate that pSivida's current employees are approximately 8% female and 92% male.

    pSivida Online Presence

    pSivida News

    pSivida Company Life

    You may also be interested in